Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation

ABSTRACT:

SUBMITTER: He C 

PROVIDER: S-EPMC11695214 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature